Lida A. Mina, MD, discusses the evolution of the antibody-drug conjugates fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine in HER2-positive breast cancer.
Lida A. Mina, MD
Advertisement
Articles by Lida A. Mina, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
DESTINY-Lung04 Showcases PFS Benefit With First-Line T-DXd in HER2-Mutant NSCLC
2
Adjuvant Osimertinib Keeps OS Benefit at 8 Years in Resected EGFR-Mutated Stage IB to IIIA NSCLC
3
PAPILLON: Frontline Amivantamab Plus Chemotherapy Yields 34.3-Month Median OS in EGFR Exon 20 Insertion–Positive NSCLC
4
Zidesamtinib Yields High Response Rates in TKI-Naive Advanced ROS1+ NSCLC
5